Dasatinib's senolytic activity was discovered via a bioinformatics screen of senescence survival networks. The key finding: senescent cells upregulate ephrin receptor (EPHA2, EPHB4) signaling, PI3K/AKT, and src-family kinases (YES1, SRC) as survival mechanisms. Dasatinib — as a multi-kinase inhibitor — simultaneously blocks these pathways, triggering apoptosis specifically in senescent cells while leaving non-senescent cells unaffected at senolytic doses.

What makes dasatinib's senolytic activity specific to senescent cells?

Two factors: (1) Senescent cells upregulate the specific kinases dasatinib inhibits (EPHA2, YES1), creating molecular selectivity. (2) The dose used for senolysis (100 mg × 2 days) is the same as for CML treatment, but the intermittent nature means it only acts during the brief window when senolytic plasma levels are maintained.

Could other kinase inhibitors also be senolytic?

Yes. This is an active research area. Navitoclax (ABT-263) is a pure BCL-2/BCL-XL inhibitor with potent senolytic activity. Several other kinase inhibitors are being screened for senolytic activity using the same bioinformatics approach.